Bloomios, Inc. (BLMS) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBloomios, Inc. (BLMS) trades at $0.0003. Bloomios, Inc. manufactures and distributes cannabidiol (CBD) products, including edibles, tinctures, and topicals, through wholesale and retail channels. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for BLMS: BLMS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Bloomios, Inc. (BLMS) Healthcare & Pipeline Overview
Bloomios, Inc. focuses on manufacturing and distributing a range of cannabidiol (CBD) products, including edibles, tinctures, and topicals. Operating within the specialty and generic drug manufacturing sector, the company targets both wholesale and retail distribution channels for its hemp-derived supplements and cosmetic products.
What Is the Investment Thesis for BLMS?
Bloomios, Inc. operates in the high-growth CBD market, but its financial performance and OTC listing present significant risks. With a negative profit margin of -226.7% and a market capitalization of $0.00B as of March 2026, the company's financial stability is uncertain. The company's gross margin stands at 36.7%. Key growth catalysts include expanding distribution channels and introducing new product lines. However, investors should be aware of the risks associated with OTC-listed companies, including limited liquidity and regulatory uncertainty. The company's ability to achieve profitability and navigate the competitive landscape will be critical to its long-term success.
Based on FMP financials and quantitative analysis
BLMS Key Highlights
Market Cap of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -0.00 reflects the company's current lack of profitability.
- Profit Margin of -226.7% highlights significant operational challenges and the need for improved cost management.
- Gross Margin of 36.7% suggests potential for profitability if operating expenses are better controlled.
- Beta of -0.53 indicates the stock is less volatile than the market, but this may also reflect limited trading activity.
Who Are BLMS's Competitors?
BLMS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| POM Pomdoctor Limited | $0.93 | +8.13% | $6.30M | 34 5-pillar |
| MEDS TRxADE HEALTH, Inc. | $3.35 | -8.97% | $8.79M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.05 | -5.29% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.45 | -0.58% | $18.7M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.82 | +3.03% | $23.1M | — |
| KYNB Kyntra Bio, Inc. | $6.09 | -3.49% | $24.7M | — |
| YI 111, Inc. | $3.15 | -2.17% | $27.5M | 39 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BLMS's Key Strengths?
Diverse product range across multiple CBD categories.
- Established wholesale and retail distribution channels.
- Focus on hemp-derived supplements and cosmetic products.
- Experienced management team in the CBD industry.
What Are BLMS's Weaknesses?
Negative profit margin and limited financial resources.
- Small market capitalization and OTC listing.
- Limited brand recognition compared to larger competitors.
- Dependence on the evolving regulatory landscape for CBD products.
What Are the Key Risks for BLMS?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Increased competition from larger companies entering the CBD market.
- Negative publicity or health concerns related to CBD products.
- Fluctuations in the price of hemp and other raw materials.
- Regulatory uncertainty and potential restrictions on CBD products.
- Limited financial resources and negative profit margin.
What Are BLMS's Competitive Advantages?
- Product diversification across multiple CBD product categories.
- Established wholesale and retail distribution channels.
- Proprietary formulations and manufacturing processes.
- Brand recognition and customer loyalty in the CBD market.
What Does BLMS Do?
Bloomios, Inc., formerly known as XLR Medical Corp., rebranded in April 2021 to concentrate on the cannabidiol (CBD) market. Incorporated in 2001 and headquartered in Santa Barbara, California, the company manufactures, markets, and distributes a diverse portfolio of CBD products. These include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats. Bloomios distributes its hemp-derived supplements and cosmetic products through both wholesale partnerships and direct retail channels, aiming to capitalize on the growing consumer interest in CBD-based health and wellness solutions. The company's strategy involves expanding its product line and distribution network to reach a broader customer base in the competitive CBD market. Bloomios faces the challenges of navigating regulatory complexities and differentiating itself in a crowded field of CBD product manufacturers and distributors. The company's success depends on effective marketing, product innovation, and adherence to quality standards to build consumer trust and brand loyalty.
What Products and Services Does BLMS Offer?
- Manufactures cannabidiol (CBD) products.
- Markets CBD products through various channels.
- Distributes CBD products to wholesale and retail customers.
- Offers edibles, tinctures, oils, salves, capsules, balms, lotions, creams, and beverages.
- Provides CBD products for both human and pet consumption.
- Sells hemp-derived supplements and cosmetic products.
How Does BLMS Make Money?
- Manufacturing and selling CBD products.
- Generating revenue through wholesale distribution to retailers.
- Generating revenue through direct-to-consumer retail sales.
- Offering a diverse range of CBD product categories to cater to different consumer preferences.
What Industry Does BLMS Operate In?
Bloomios, Inc. operates within the rapidly expanding CBD market, which has seen significant growth due to increasing consumer acceptance of CBD products for various health and wellness applications. The market is characterized by intense competition, with numerous companies offering similar products. Key trends include the development of innovative CBD formulations, the expansion of distribution channels, and increasing regulatory scrutiny. Bloomios competes with other CBD manufacturers and distributors, including AIDA, ASFX, CENBF, MJNE, and SAGD, all of which are navigating the evolving regulatory landscape and striving to establish brand recognition.
Who Are BLMS's Key Customers?
- Retail consumers seeking CBD products for health and wellness.
- Wholesale distributors and retailers selling CBD products.
- Pet owners seeking CBD products for their pets.
- Customers interested in various forms of CBD consumption (e.g., edibles, topicals, tinctures).
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Bloomios, Inc. operates in the Healthcare sector. It is headquartered in Santa Barbara, US. The company is led by CEO Michael Hill. BLMS has traded publicly since 2003.
Insider Activity
12 transactions · 0 purchases, 1 sales, 11 other transactions · 9 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Financial Health
Bloomios, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on assets is -53.0%, showing how much profit it generates from its asset base. A current ratio of 0.09 means current liabilities exceed short-term assets, a liquidity point worth watching.
BLMS Financials
BLMS Latest News
No recent news available for BLMS.
BLMS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BLMS.
Price Targets
Wall Street price target analysis for BLMS.
BLMS MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BLMS; grades run from A+ (80-100) to F (below 30).
Leadership: Michael Hill
CEO
Michael Hill serves as the CEO of Bloomios, Inc., managing a small team of three employees. His leadership is focused on guiding Bloomios in the competitive CBD market, navigating regulatory challenges, and driving growth through product innovation and distribution expansion.
Track Record: Due to limited information on Michael Hill's prior experience and specific achievements at Bloomios, it is difficult to assess his track record. His success will be measured by the company's ability to achieve profitability, expand its market share, and navigate the evolving regulatory landscape for CBD products.
BLMS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Bloomios, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to provide regular financial disclosures, increasing the risk for investors compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited liquidity due to low trading volume on the OTC market.
- Lack of transparency due to potentially limited financial disclosures.
- Higher price volatility compared to stocks listed on major exchanges.
- Potential for pump-and-dump schemes or other fraudulent activities.
- Regulatory uncertainty surrounding CBD products and the company's operations.
- Verify the company's financial statements and SEC filings (if available).
- Research the background and experience of the company's management team.
- Assess the company's competitive position in the CBD market.
- Evaluate the company's compliance with relevant regulations.
- Monitor news and press releases for any red flags or potential risks.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- The company has been in operation since 2001.
- Bloomios has a diverse product range across multiple CBD categories.
- The company has established wholesale and retail distribution channels.
- Bloomios rebranded in 2021 to focus on the CBD market, indicating a strategic shift.
- The company's headquarters are located in Santa Barbara, California.
BLMS Healthcare Stock FAQ
What does Bloomios, Inc. do?
Bloomios, Inc. is a manufacturer and distributor of cannabidiol (CBD) products, catering to both human and pet consumption. The company offers a diverse range of CBD products, including edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats.
What do analysts say about BLMS stock?
As of March 2026, there is no readily available analyst coverage for Bloomios, Inc. (BLMS) due to its OTC listing and small market capitalization. Key valuation metrics, such as P/E ratio and profit margin, indicate financial challenges.
What revenue streams does Bloomios, Inc. have in healthcare?
Bloomios, Inc. generates revenue primarily through the sale of its cannabidiol (CBD) products. These revenue streams are derived from both wholesale and retail distribution channels.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on CEO background and track record.
- Financial data based on available information and may not be comprehensive.
- OTC market investments carry higher risk than exchange-listed stocks.